Proton and Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy of Human Bile in Hepatopancreaticobiliary Cancer
Overview
Authors
Affiliations
Objective: Hepatopancreaticobiliary cancers can be difficult to diagnose. Nuclear magnetic resonance (NMR) spectroscopy provides non-invasive information on phospholipid metabolism, and previous studies of liver tissue have highlighted changes in phospholipids in malignancy. We hypothesised that in-vitro NMR spectroscopy of human bile may provide independent diagnostic indices in cancer management through an assessment of the phospholipid content.
Design And Methods: Bile samples from 24 patients were collected at endoscopic retrograde cholangiopancreatography and from one subject at cholecystectomy. Thirteen patients had cancer: pancreatic carcinoma (eight), cholangiocarcinoma (three) and metastatic liver disease (two). The remaining 12 patients had non-malignant pathology. In-vitro proton (H) and phosphorus-31 (P) NMR spectra were obtained from all samples using an 11.7 Tesla NMR spectroscopy system.
Results: Complementary information was obtained from the H and P NMR spectra. Signals were assigned to phosphatidylcholine in both H and P NMR spectra. Phosphatidylcholine levels were significantly reduced in the bile from cancer patients when compared with bile from non-cancer patients (P=0.007).
Conclusion: These preliminary studies suggest that H and P NMR spectroscopy of bile may be used to detect differences in phospholipid content between cancer and non-cancer patients. This may have implications for the development of novel diagnostic strategies in hepatopancreaticobiliary cancers. Further larger-scale studies are warranted.
Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
Li Y, Li K, Liu Z, Tang Y, Hu X, Li X Front Immunol. 2022; 13:1049812.
PMID: 36389727 PMC: 9649822. DOI: 10.3389/fimmu.2022.1049812.
Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.
Bao F, Liu J, Chen H, Miao L, Xu Z, Zhang G Cancers (Basel). 2022; 14(16).
PMID: 36010914 PMC: 9406189. DOI: 10.3390/cancers14163921.
Urman J, Herranz J, Uriarte I, Rullan M, Oyon D, Gonzalez B Cancers (Basel). 2020; 12(6).
PMID: 32575903 PMC: 7352944. DOI: 10.3390/cancers12061644.
Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort.
Alsaleh M, Leftley Z, Barbera T, Koomson L, Zabron A, Crossey M J Clin Exp Hepatol. 2020; 10(1):17-29.
PMID: 32025163 PMC: 6995894. DOI: 10.1016/j.jceh.2019.06.001.
Alsaleh M, Barbera T, Reeves H, Cramp M, Ryder S, Gabra H Hepat Med. 2019; 11:47-67.
PMID: 31118840 PMC: 6507078. DOI: 10.2147/HMER.S193996.